medigraphic.com
Boletín Clínico de la Asociación Médica del Hospital Infantil del Estado de Sonora

2022, Number 2

<< Back Next >>

Bol Clin Hosp Infant Edo Son 2022; 39 (2)

Presence of the Attention Deficit Hyperactivity Disorder in the adolescent and its associated impact to the consumption of substances

Hernández-Lira S, Reyes-Gómez U, Reyes-Hernández KL, Perea-Martínez A, Reyes-Hernández MU, Aguilar-Román AB, Pineda-Gordillo A, Hernández-Lira I, López-Cruz G, Quero-Hernández A, Ríos-GallardoPT, Mayrel-Santiago-Lagunes L, Yalaupari-Mejía JP, Arellano-Galindo J

Language: Spanish
References: 21
Page: 56-62
PDF size: 209.74 Kb.


ABSTRACT

Attention Deficit Hyperactivity Disorder (ADHD), is the most common neurodevelopmental disorder of childhood, characterized by distractibility, disinhibition, impulsivity and hyperactivity, which if not detected in the child’s age, it can prevail adolescence and adulthood, where clinical characteristics of impulsivity and inattention are more frequent, since hyperactivity decreases with age. This disorder presents multiple comorbidities, among the most important is the use of substance, starting at an early age and that is perpetuated throughout the life of the individual, reaching a significant impact causing dysfunction in multiple areas where the individual develops. Once it detected this common dual pathology is necessary to initiate a multidisciplinary treatment where there should be a pharmacological treatment that associated with cognitive behavioral therapy reinsert the patient into adequate global functionality.


REFERENCES

  1. Barceló ME. Validación del inventario exploratoriode síntomas de TDAH (IES-TDAH) ajustado alDSM-V. Rev Mex Neuro. 2016; 17(1): 12-22.

  2. Ramos QJ. TDAH en adultos: factores genéticos,evolutivos y tratamiento Farmacológico. Tesis deGrado Psiquiatría y Psicología Clínica. Barcelona,España: Universidad de Barcelona; 2009.

  3. Martínez RJ, Knecht C, Szerman N. Patologíadual: protocolos de intervención TDAH. Edikamed.2012.

  4. Casas AM. Relaciones entre funciones ejecutivasy calidad de vida de jóvenes con trastorno pordéficit de atención con hiperactividad (TDAH). InternationalJournal of Developmental and EducationalPsychology. Revista INFAD de Psicología.2016; 2(1): 301-10.

  5. Ohlmeier MD. Comorbilidad de la Dependenciaa Alcohol y Drogas y el Trastorno por Déficit deAtención e Hiperactividad (TDAH). RET: Revistade toxicomanías. 2009; 58: 12-18.

  6. American Psychiatric Association. Diagnostic andstatistical manual of mental disorders. [5.ta Ed.].Arlington: American Psychiatric Publishing; 2013.

  7. Wilens TE, Upadhyaya HP. Impact of substanceuse disorder on ADHD and its treatment. J ClinPsychiatry. 2007; 68: e20.

  8. Charach A, Yeung E, Climans T, Lillie E. Childhoodattention-deficit/hyperactivity disorder and futuresubstance use disorders: comparative meta-analyses. J Am Acad Child Adolesc Psychiatry.2011; 50: 9-21.

  9. Johann M, Bobbe G, Laufkötter R, Lange K, WodarzN. (Attention-deficit hyperactivity diso rderand alcohol dependence: a risk constellation).Psychiatr Prax. 2004; 31 (Suppl 1): 102-4.

  10. Graham NA, DuPont RL, Gold MS. Symptoms ofADHD or marijuana use? Am J Psychiatry. 2007;164: 973-5.

  11. Ros A, Valoria A, Nieto J. Consumo de cocaína yotros psicoestimulantes: su relación con el síndromede hiperactividad infantil. Actas Esp Psiquiatría.2004; 32: 346-52.

  12. Vergara ME, et al. Diagnóstico del trastorno pordéficit de atención e hiperactividad (TDAH) en pacientesadultos con dependencia de cocaína: utilidadde los nuevos síntomas de funcionamientoejecutivo de Barkley. Trastornos adictivos. 2010;12(2): 72-8.

  13. Wilen ST, Adam SJ, Monuteaux MC, Faraon SV,Schillinger M, Westerberg D, Biederman J. Effectof prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarettesmoking and alcohol and drug use disordersin adolescents. Arch Pediatr Adolesc Med. 2008;162: 916-21.

  14. Davids E, Von Bünau U, Specka M, Fischer B,Scherbaum N, Gastpar M. History of attention-deficithyperactivity disorder symptoms and opioiddependence: a controlled study. Prog NeuropsychopharmacolBiol Psychiatry. 2005; 29: 291-6.

  15. Bhatara V, Loudenberg R, Ellis R. Association ofattention deficit hyperactivity disorder and gestationalalcohol exposure: an exploratory study. JAtten Disord. 2006; 9: 515-22.

  16. Schubiner A, Howard. D. Substance abuse in patientswith attention-deficit hyperactivity disorder.CNS drugs, 2005; 19(8): 643-55.

  17. Ramos QJ. Trastorno por déficit de atención conhiperactividad (TDAH) y drogodependencias. RET:Revista de toxicomanías. 2007; 50: 23-8.

  18. Aragones E. Cribado Para El Trastorno Por DéficitDe Atención/Hiperactividad En Pacientes AdultosDe Atención primaria. Revista de Neurología.2013; 56(9): 49-55.

  19. Rezaei F, Emami M, Zahed S, Morabbi MJ, FarahzadiM, Akhondzadeh S. Sustained-release methylphenidatein methamphetamine dependencetreatment: a double-blind and placebo-controlledtrial. Daru. 2015; 15(23): 2.

  20. Emilsson B, Gudjonsson G, Sigurdsson JF, BaldurssonG, Einarsson E, Olafsdottir H, et al. Cognitivebehavior therapy in medication-treated adultswith ADHD and persistent symptoms: A randomizedcontrolled trial. BMC Psychiatry. 2011; 25(1):116.

  21. Vidal ER, Bosch MR, Nogueira MM, Casas BM,Ramos QJ. Tratamiento psicológico del trastornopor déficit de atención con hiperactividad enadultos: revisión sistemática. Acta Esp Psiquiatr.2012; 40(3): 147-54.




2020     |     www.medigraphic.com